Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by LPL Financial LLC

LPL Financial LLC raised its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 6.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,485 shares of the company’s stock after buying an additional 646 shares during the quarter. LPL Financial LLC’s holdings in Structure Therapeutics were worth $311,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in GPCR. State Street Corp raised its stake in Structure Therapeutics by 27.0% during the third quarter. State Street Corp now owns 12,295 shares of the company’s stock worth $540,000 after purchasing an additional 2,611 shares during the period. Barclays PLC grew its stake in Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after purchasing an additional 31,815 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after buying an additional 312 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Structure Therapeutics by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 706,106 shares of the company’s stock worth $30,991,000 after purchasing an additional 60,397 shares during the last quarter. Finally, Exome Asset Management LLC acquired a new stake in Structure Therapeutics during the third quarter valued at approximately $5,274,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GPCR shares. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $23.74 on Monday. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74. The business’s fifty day moving average price is $20.17 and its two-hundred day moving average price is $27.71. The company has a market capitalization of $1.36 billion, a P/E ratio of -32.08 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. On average, research analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.